Form 4: Roivant Sciences CEO Exercises Options, Sells Shares

Roivant Sciences' President & Immunovant CEO, Eric Venker, exercised stock options and subsequently sold 200,000 common shares for a significant gain.

Summary

• Eric Venker, President & Immunovant CEO of Roivant Sciences Ltd. (ROIV), reported a transaction involving the company's common shares.
• On March 17, 2026, Venker acquired 200,000 common shares by exercising stock options at a price of $3.85 per share.
• Immediately following the acquisition, Venker disposed of 200,000 common shares at a weighted average price of $28.24 per share.
• The sale price ranged from $28.04 to $28.45 per share.
• This transaction was made pursuant to a Rule 10b5-1(c) contract, instruction, or written plan.
• Following these transactions, Venker's direct beneficial ownership of common shares decreased from 1,847,546 to 1,647,546.
• Venker still beneficially owns 4,844,834 stock options (right to buy) after the reported transaction.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a routine insider transaction under a 10b5-1 plan, indicating a planned diversification or liquidity event rather than a signal of negative company performance. The significant profit realized is a positive for the executive.

Positives

• The reporting person realized a significant profit from exercising options at $3.85 and selling shares at a weighted average of $28.24.

Negatives

• The sale of 200,000 common shares by a key executive could be perceived as a reduction in insider exposure, although it was a pre-planned transaction.

Future Outlook

This Form 4 filing does not contain any forward-looking statements or guidance regarding the company's future performance or outlook.

Industry Context

StockSavvy.ai notes that insider transactions, particularly sales, are closely watched by the market for signals about management's confidence. However, this transaction was explicitly made pursuant to a Rule 10b5-1(c) plan, which indicates it was pre-scheduled and not based on new material non-public information. Such planned sales are common for executives managing personal finances and diversifying holdings.

Stakeholder Impact

• Shareholders may observe the executive's sale of shares, but the 10b5-1 plan context suggests it is a pre-arranged personal financial decision rather than a reflection of company-specific news.

Key Dates

Recommendation

The reported transaction is a pre-planned exercise of stock options and subsequent sale of shares by an executive, likely for personal financial planning and diversification. It does not provide new fundamental information about Roivant Sciences' operational performance or strategic direction that would warrant a change in investment recommendation based solely on this filing.

Keywords

Roivant Sciences, ROIV, Eric Venker, Insider Transaction, Form 4, Stock Options, Share Sale, 10b5-1 Plan, Immunovant